Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214857 · ClinicalTrials.gov registry record
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,385
- Enrollment target
NCT07214857: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07214857 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,385 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07214857 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,385 participants
- Enrollment target
Study Summary
The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran based on US National Health and Nutrition Examination Survey (NHANES) data and inclisiran eligibility criteria from ongoing clinical trials as well as to estimate the number of preventable ASCVD events based on expected risk reductions from the degree of low-density lipoprotein cholesterol (LDL-C) lowering expected from inclisiran. This study used data from the US NHANES 2011-2020 surveys. NHANES is a national survey which collects medical history, laboratory, and medication information from participants of all ages.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,385 participants |
| Start Date | 2024-03-29 |
| Est. Completion | 2024-10-09 |
What the finished NCT07214857 record still lists
NCT07214857 is an observational study that tracks outcomes without assigning an intervention. Its 1,385 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07214857 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07214857 about?
NCT07214857 is a clinical study titled "Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States". The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran based on US National Health and Nutrition Examination Survey (NHANES) data and inclisiran eligibility cr...
What is the current status of trial NCT07214857?
This trial is currently completed. The enrollment target is 1,385 participants. The study started on 2024-03-29. Estimated completion is 2024-10-09.
Who is sponsoring clinical trial NCT07214857?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06651281 · 1,380 participants · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- NCT05006131 · 1,395 participants
Pancreatic Cancer Screening for At-risk Individuals
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI